Karl J. Puttlitz

Array ( [id] => 17368387 [patent_doc_number] => 20220023439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/290694 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 316 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18232149 [patent_doc_number] => 11596693 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Antibody-drug conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 16/650226 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9454 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297950 [patent_doc_number] => 20210393789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates [patent_app_type] => utility [patent_app_number] => 17/287792 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590189 [patent_doc_number] => 11739069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Modulators of resistant androgen receptor [patent_app_type] => utility [patent_app_number] => 16/658245 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 26487 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16658245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493091 [patent_doc_number] => 20200046734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => Methods of Reducing Mammographic Breast Density and/or Breast Cancer Risk [patent_app_type] => utility [patent_app_number] => 16/656273 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16656273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503547 [patent_doc_number] => 20220096649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/283919 [patent_app_country] => US [patent_app_date] => 2019-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328449 [patent_doc_number] => 12458706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Compounds and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 17/284388 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 39 [patent_no_of_words] => 25372 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15738529 [patent_doc_number] => 20200108152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-09 [patent_title] => ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/594728 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15863127 [patent_doc_number] => 20200138967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => COMBINATION THERAPY USING ANTI-SSEA-4 ANTIBODY IN COMBINATION WITH THERAPEUTIC ONCOLOGY AGENTS [patent_app_type] => utility [patent_app_number] => 16/590967 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16590967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087087 [patent_doc_number] => 20200197530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => DELTA-OPIOID RECEPTOR TARGETED AGENT FOR MOLECULAR IMAGING AND IMMUNOTHERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 16/587720 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16587720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15360975 [patent_doc_number] => 20200016252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => CYCLOPHOSPHAMIDE ANALOGS FOR USE AS IMMUNOGENS AND ASSAY CONJUGATES FOR AN IMMUNOASSAY OF CYCLOPHOSPHAMIDE AND IFOSFAMIDE [patent_app_type] => utility [patent_app_number] => 16/586546 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19241069 [patent_doc_number] => 12011485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Sulfomaleimide-based linkers and corresponding conjugates [patent_app_type] => utility [patent_app_number] => 17/280800 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 53 [patent_no_of_words] => 38195 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 259 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16296194 [patent_doc_number] => 20200281917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 [patent_app_type] => utility [patent_app_number] => 16/584272 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16584272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17755534 [patent_doc_number] => 11395812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Docetaxel albumin nanoparticle pharmaceutical composition, preparation method therefor and use thereof [patent_app_type] => utility [patent_app_number] => 16/582295 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8607 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16582295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20687732 [patent_doc_number] => 12617867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof [patent_app_type] => utility [patent_app_number] => 17/280129 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 9 [patent_no_of_words] => 34491 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16189259 [patent_doc_number] => 20200230108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => PHARMACEUTICAL COMBINATIONS [patent_app_type] => utility [patent_app_number] => 16/580505 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646619 [patent_doc_number] => 20200085839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING LYMPHOMAS [patent_app_type] => utility [patent_app_number] => 16/580178 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16580178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342415 [patent_doc_number] => 20200009099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SCHISTOSOMIASIS [patent_app_type] => utility [patent_app_number] => 16/576395 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17458840 [patent_doc_number] => 20220072144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => TREATMENT OF HER3-MUTATED CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/276394 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696761 [patent_doc_number] => 10604547 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase [patent_app_type] => utility [patent_app_number] => 16/574500 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 31877 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16574500 [rel_patent_id] =>[rel_patent_doc_number] =>)